Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Medroxyprogesterone Acetate: Research Workflows
2026-08-26
Build reproducible MPA experiments for progesterone signaling, renal epithelial biology, reproductive models, and neurobiology. This workflow emphasizes solvent control, receptor-aware interpretation, and practical translation of a recent endometrial senescence study into assay design.
-
Biophysical Mapping of LNP Structure–Function Relationships
2026-08-26
Padilla and colleagues combine sedimentation velocity analytical ultracentrifugation, field-flow fractionation with multiangle light scattering, and SEC–SAXS to characterize lipid nanoparticles in solution. Their findings show that LNP size, RNA loading, and shape are intrinsically heterogeneous and depend on both lipid composition and mixing method, offering a stronger basis for linking particle properties to mRNA translation.
-
β-Amanitin: From Transcription to Translation
2026-08-25
β-Amanitin is more than a toxicological reference compound: it is a mechanistically defined perturbation tool for linking RNA polymerase II activity to cellular phenotypes and translational assay performance. This article outlines how to use beta-amanitin in transcription studies, interpret evidence from emerging amatoxin detection platforms, and select a research-grade workflow without overstating clinical relevance.
-
Torin2: Selective mTOR Inhibitor for Cancer Research
2026-08-25
Torin2 is a potent, selective mTOR inhibitor for mechanistic cancer research, with a reported EC50 of 0.25 nM and oral bioavailability. Its documented activity in medullary thyroid carcinoma models supports applications in viability, migration, apoptosis, and combination-treatment assays.
-
7-dehydro Cholesterol: Assays, UVB & DHCR7
2026-08-24
7-dehydro Cholesterol links DHCR7-dependent sterol metabolism with UVB-driven vitamin D3 formation, oxidative lipid biology, and immune research. This practical guide covers stock preparation, cell and skin-model workflows, assay controls, and lessons from dhcr7-edited grass carp.
-
Vitamin D/VDR Drives Endometrial Decidualization
2026-08-24
This study identifies the vitamin D/VDR system as a regulator of human endometrial stromal cell decidualization, linking vitamin D signaling to CYP19-mediated estrogen production and established decidual markers. Its combined use of time-course profiling, VDR perturbation, primary cells, and ChIP-qPCR provides a mechanistic framework for studying endometrial receptivity and infertility biology.
-
Medroxyprogesterone Acetate: Assay Design Guide
2026-08-23
Explore how Medroxyprogesterone acetate (MPA) can be used as a controlled steroid-signaling perturbation across reproductive, renal, and neurobiological assays. This guide connects receptor mechanism, solubility, model selection, and vitamin D/VDR research to improve causal interpretation.
-
DMG-PEG2000-NH2 for Reliable Viability Studies
2026-08-22
Learn how DMG-PEG2000-NH2 (SKU M2006) can improve the interpretability of cell viability and cytotoxicity workflows by standardizing lipid conjugation, solvent handling, and formulation controls. This scenario-based guide separates evidence-supported product properties from assay-specific recommendations.
-
Medroxyprogesterone acetate: Applied Research Workflows
2026-08-22
Medroxyprogesterone acetate (MPA) provides a controllable steroid signal for decidualization, renal epithelial, and neuroendocrine studies. This guide connects solvent handling and dose design with metabolic readouts, troubleshooting, and tissue-specific interpretation.
-
Carvedilol in β-Adrenergic Receptor Research
2026-08-21
Carvedilol combines nonselective β-adrenergic and α1-adrenergic receptor blockade with measurable antioxidant and vascular effects. This guide translates those properties into practical receptor, oxidative-stress, vascular, and hematopoietic workflows, including controls inspired by recent transplantation research.
-
Tunable Human Intestinal Organoids: Study Insights
2026-08-20
The reference study develops a human small intestinal organoid system that couples strong stem-cell self-renewal with broad epithelial differentiation under a single culture condition. Its central innovation is to amplify stemness before directing cell fate, enabling reversible or lineage-selective control without recreating artificial spatial signaling gradients.
-
T0070907 as a Causal PPARγ Signaling Probe
2026-08-20
T0070907 is a high-affinity PPARγ antagonist for separating receptor-dependent transcription from downstream cellular phenotypes. This article develops an assay strategy linking PPARγ/RXRα heterodimer modulation to adipogenesis, macrophage inflammation, and cell cycle G2/M arrest without overinterpreting pathway associations.
-
GS967: Cardiac Late Sodium Current Workflows
2026-08-19
GS967 enables targeted interrogation of pathological late Na⁺ influx across ventricular myocyte, isolated-heart, aging, and ischemia models. This workflow-focused guide combines concentration planning, electrophysiology controls, arrhythmia endpoints, and troubleshooting for more reproducible cardiac research.
-
Fucoidan, CPT-11, and the Gut–Liver Axis
2026-08-19
The reference study identifies intestinal barrier failure, circulating bacterial LPS, and hepatic neutrophil extracellular traps as a mechanistic pathway linking CPT-11 exposure to chemotherapy-induced steatohepatitis. Its fucoidan intervention partially restored gut integrity, moderated microbiota disruption, reduced LPS translocation, and suppressed hepatic NET accumulation, providing a framework for studying irinotecan-associated liver injury.
-
T0070907: A Practical PPARγ Antagonist Guide
2026-08-18
T0070907 is a high-affinity, covalent PPARγ antagonist for separating receptor-dependent transcription from downstream cellular phenotypes. This guide shows how to deploy it in adipogenesis, macrophage foam-cell, and cervical cancer workflows while controlling solvent, timing, and PPARγ-independent effects.